Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 16/20 | 0.85 |
| ▸ | PPARG | P37231 | 16/20 | 0.85 |
| ▸ | PPARD | Q03181 | 2/20 | 0.69 |
| ▸ | TSPO | P30536 | 2/20 | 0.45 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7531486 | 1.00 | PPARA (0.85) | PPARAPPARGPPARDTSPOPGR | |
| SCHEMBL7536345 | 0.95 | PPARA (0.83) | PPARAPPARGPPARDPGRADORA3 | |
| SCHEMBL7528811 | 0.92 | PPARG (1.00) | PPARAPPARGPPARDPGRADORA3 | |
| SCHEMBL7856304 | 0.92 | PPARG (1.00) | PPARAPPARGPPARDPGRADORA3 | |
| SCHEMBL7527968 | 0.92 | PPARG (0.82) | PPARAPPARGPPARDPGRADORA3 | |
| SCHEMBL7527971 | 0.92 | PPARG (0.82) | PPARAPPARGPPARDPGRADORA3 | |
| SCHEMBL7524312 | 0.88 | PPARA (0.71) | PPARAPPARGPPARDTSPOPGR | |
| SCHEMBL7524309 | 0.88 | PPARA (0.71) | PPARAPPARGPPARDTSPOPGR | |
| SCHEMBL7533755 | 0.87 | PPARA (1.00) | PPARAPPARGPPARDPGRADORA3 | |
| SCHEMBL7845343 | 0.84 | PPARG (0.83) | PPARAPPARGPPARDTSPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6468996-B1 | PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ACTIVATORS; TREATMENT OF DIABETES AND OBESITY. | NOVO NORDISK A/S (DK) | 2002-10-22 | — | — | US | disclosed |
| US-20020115657-A1 | Substituted hetero-polycyclic compounds as PPARalpha and PPARgamma | JEPPESEN LONE (DK) | 2002-08-22 | — | — | US | disclosed |
| US-20020111344-A1 | Substituted hetero-polycyclic compounds as PPARalpha and PPARgamma activators | JEPPESEN LONE (DK) | 2002-08-15 | — | — | US | disclosed |
| US-20020103188-A1 | Substituted hetero-polycyclic compounds as PPARalpha and PPARgamma activators | JEPPESEN LONE (DK) | 2002-08-01 | — | — | US | disclosed |
| EP-1123279-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2001-08-16 | — | — | EP | disclosed |
| WO-2000023425-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103188-A1 | Substituted hetero-polycyclic compounds as PPARalpha and PPARgamma activators | PPARG, PPARA, PPARD | PPARA 2/4885PPARG 1/4885PPARD 3/4885 |
| US-20020115657-A1 | Substituted hetero-polycyclic compounds as PPARalpha and PPARgamma | PPARG, PPARA, PPARD | PPARA 2/4885PPARG 1/4885PPARD 3/4885 |
| US-20020111344-A1 | Substituted hetero-polycyclic compounds as PPARalpha and PPARgamma activators | PPARG, PPARA, PPARD | PPARA 2/4885PPARG 1/4885PPARD 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.